August 11, 2014
Weil is advising global pharmaceutical and healthcare firm Sanofi on its worldwide exclusive licensing agreement with MannKind Corporation to develop and commercialize Afrezza (insulin human) Inhalation Powder.
Afrezza is a new rapid-acting inhaled insulin therapy indicated to improve glycemic control in adult patients with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
The Weil team on this transaction includes Technology & IP Transactions partner Jeffrey Osterman and associates Cassie Waduge and Dennis Adams; Banking & Finance partner Douglas Urquhart, and associates Heather Viets and Alison Carrizales; Antitrust partner John Scribner, and counsel Vadim Brusser; and Litigation partner Yehudah Buchweitz.